Gabapentin on Day of Brain Injury Linked to 22% Lower Cognitive Impairment Risk
A 50,000-patient study finds same-day gabapentin after TBI cuts cognitive impairment risk by 22% and mortality by 46% in severe cases.
Summary
Researchers analyzing health records from nearly 50,000 traumatic brain injury patients found that gabapentin given on the day of injury was associated with significantly better outcomes. Over two years, mild TBI patients who received gabapentin had a 22% lower risk of developing lasting cognitive impairment, while severe TBI patients showed a 46% lower risk of death. The drug, originally developed as an anti-seizure medication, is already commonly used after brain injury for pain and agitation. Scientists from Johns Hopkins and New York Medical College believe gabapentin may offer neuroprotective effects beyond symptom management. However, longer-term use was linked to psychiatric, sleep, and cardiovascular side effects, underscoring the need for careful risk-benefit evaluation.
Detailed Summary
Traumatic brain injury affects millions annually and remains one of medicine's most stubborn challenges, with few therapies proven to meaningfully reduce long-term cognitive decline or disability. A new large-scale retrospective study now suggests that gabapentin, a widely used and well-tolerated medication, may offer unexpected neuroprotective benefits when administered on the day of injury.
Researchers from Johns Hopkins University and New York Medical College analyzed electronic health records from 49,925 adult TBI patients enrolled in the multinational TriNetX Research Network. All patients had a Glasgow Coma Scale score recorded on the day of injury. Those with prior cognitive impairment or previous gabapentin use were excluded to reduce confounding. Adjusted Cox survival models tracked outcomes over two years.
The headline findings are striking. Patients with mild TBI who received same-day gabapentin had a 22% lower adjusted risk of developing durable cognitive impairment, defined as diagnoses of Alzheimer's disease, vascular dementia, or mild cognitive impairment. In severe TBI cases, gabapentin was associated with a 46% lower risk of all-cause mortality. These are statistically significant associations that warrant serious scientific attention.
The research team was motivated by earlier work on levetiracetam, another anti-seizure drug, which showed limited benefit beyond early seizure prevention. Gabapentin's broader pharmacological profile, including effects on pain signaling and neural excitability, may explain why it could modify downstream injury cascades rather than merely treating surface symptoms. The biological plausibility is real, though not yet fully mapped.
Important caveats apply. This is a retrospective, observational study, meaning causation cannot be confirmed. Longer-term gabapentin use was associated with psychiatric, sleep, and cardiovascular disorders, raising safety concerns. The findings were presented as a conference poster, not yet peer-reviewed in full. Prospective clinical trials are needed before any clinical protocol changes are warranted.
Key Findings
- Same-day gabapentin linked to 22% lower cognitive impairment risk in mild TBI over 2 years
- Severe TBI patients receiving gabapentin showed 46% lower all-cause mortality risk at 2 years
- Study drew from nearly 50,000 real-world TBI patients across a multinational health network
- Long-term gabapentin use associated with psychiatric, sleep, and cardiovascular adverse effects
- Researchers hypothesize gabapentin may act as a neuroprotective agent, not just a symptom reliever
Methodology
This is a news report from MedPage Today covering a poster presentation at the American Academy of Neurology 2026 annual meeting. The underlying study is a retrospective, longitudinal cohort analysis using the TriNetX multinational health records network with nearly 50,000 patients and adjusted Cox proportional hazards models. The findings have not yet undergone full peer-reviewed journal publication.
Study Limitations
As a retrospective observational study, causation cannot be established and unmeasured confounders may influence results. The study was presented as a conference poster and has not yet been peer-reviewed or published in a full journal article. Long-term adverse effects including psychiatric and cardiovascular risks must be weighed carefully against potential cognitive benefits.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.